About US
Contact us
-
GlaxoSmithKline jumps into myeloma with 'homemade' anti-BCMA drug BlenrepBack in 2015, GlaxoSmithKline traded away its marketed cancer assets and began building its oncology pipeline “pretty aggressively,” as Axel Hoos, the company’s SVP of Oncology R&D, puts it. Thos2020/8/6
-
Takeda hustles to prevent cancer drug shortage after FDA warning letterTakeda took a slap from the FDA in June when inspectors slammed its Hikari, Japan, plant in a warning letter. It turns out that fixing those problems helped triggera local shortage of the chemotherap2020/8/5
-
Regeneron rises on Eylea, Dupixent strength as COVID-19 antibody funding pours inIn stark contrast to many drugmakers registeringsecond-quarter declines, Regeneron pulled off a 24% revenue increase on the strength of Eylea and Dupixent sales, as well as a U.S. government supply d2020/8/5
-
Pfizer's Lorbrena makes play for earlier lung cancer use with Xalkori-topping dataIf Pfizer wants targeted lung cancer med Lorbrena to be a true follow-up to Xalkori, it has to get the product cleared in previously untreated ALK-positive patients. And it just took a step toward ac2020/8/4
-
Johnson & Johnson pledges 100M coronavirus vaccine doses to U.S. for $10 eachWith leading COVID-19 vaccines in late-stage testing, companies have been inking supply deals with the U.S. government for a quick rollout if their programs succeed. Now, Johnson & Johnson is get2020/8/4
-
Amgen's psoriasis pill Otezla thrives amid pandemic against injectable rivalsAs companiesworldwide grapple with sales challenges from the COVID-19 pandemic, Amgen is getting a boost from its newly acquired immunology blockbuster Otezla. The medicine, picked up from Celgene2020/7/30
-
Roche arthritis drug Actemra flunks COVID-19 study, but remdesivir combo data awaitYet anotherattempt at repurposing existing drugs for COVID-19 has fallen short. Roche’s arthritis med Actemrafailed tobeat placebo at significantly improving clinical status among patients with se2020/7/30
-
Pfizer CEO: We may cut jobs, backpedal on expansions if Trump's pricing orders take effectPresident Donald J. Trump's recent spate of executive orders targeting U.S. drug prices has received heaps of scorn from the pharmaceutical industry and its lobbyists. Now, Pfizer says Trump's mandat2020/7/29
-
Camera maker Kodak dives into drug manufacturing with $765M federal loanWith COVID-19 straining international relations over the supply of needed generic medicines, the U.S. has scrambled to pump up domestic production of those key drugs. Now, the government is making a2020/7/29
-
Vyndaqel, Ibrance boost Pfizer as it eyes COVID-19 vaccine launch this yearAdd another name to the list of pharmas reporting sales declines amid the pandemic. But this company, Pfizer, is still dialing up its full-year revenue expectations—not that it’s counting any contrib2020/7/28